Key Insights

Highlights

Success Rate

88% trial completion (above average)

Published Results

14 trials with published results (14%)

Research Maturity

59 completed trials (58% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

7.8%

8 terminated out of 102 trials

Success Rate

88.1%

+1.6% vs benchmark

Late-Stage Pipeline

27%

28 trials in Phase 3/4

Results Transparency

24%

14 of 59 completed with results

Key Signals

14 with results88% success

Data Visualizations

Phase Distribution

82Total
Not Applicable (28)
P 1 (7)
P 2 (19)
P 3 (12)
P 4 (16)

Trial Status

Completed59
Unknown28
Terminated8
Withdrawn4
Recruiting1
Active Not Recruiting1

Trial Success Rate

88.1%

Benchmark: 86.5%

Based on 59 completed trials

Clinical Trials (102)

Showing 20 of 20 trials
NCT02879422Not ApplicableCompletedPrimary

Genetic Markers and Proliferative Diabetic Retinopathy

NCT07315802Not ApplicableNot Yet RecruitingPrimary

New Pattern of Retinal Laser Treatment for PDR

NCT07054281Not ApplicableWithdrawn

UNITY VCS Vitreoretinal Surgery

NCT06549023Not ApplicableRecruitingPrimary

Single Session vs Multiple-Session Panretinal Photocoagulation for Treatment of Proliferative Diabetic Retinopathy

NCT04278417Phase 3CompletedPrimary

Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy

NCT07144865Not ApplicableCompletedPrimary

Biological Changes in Fibrovascular Membranes of Patients With Proliferative Diabetic Retinopathy Following Faricimab Injection

NCT06583798Completed

Outcomes of Retinal Re-surgeries in Silicone Oil Filled Eyes

NCT05169502Completed

Discovering Early Biomarkers in Circulating Endothelial Cells for Diabetes Complications by Single Cell RNA Sequencing

NCT05677685Not ApplicableCompleted

VISUPRIME® Eye Drops

NCT05393284Phase 2Active Not Recruiting

Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy

NCT00600236Phase 3Withdrawn

HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population

NCT01737957Not ApplicableTerminatedPrimary

Safety and Efficacy of Low-Fluence PRP for PDR

NCT01568242Not ApplicableWithdrawnPrimary

Changes in Vitreous Temperature During Phacoemulsification

NCT00802269Phase 4TerminatedPrimary

Pain Using Reduced Fluence Parameters in Photocoagulation for Diabetic Retinopathy.

NCT00600262Phase 2Terminated

Intravitreal Bevacizumab for Diabetic Retinopathy

NCT00563628Phase 4Terminated

Changes in Macular Thickness After Patterns Scan Laser

NCT00563043Phase 4Terminated

Changes in Electroretinogram and Contrast Sensitivity After PASCAL Treatment

NCT01478737Phase 2CompletedPrimary

Intravitreal Ozurdex After Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy

NCT04674254Phase 4CompletedPrimary

Macular Perfusion Changes After Anti-VEGF Versus Targeted Retinal Photocoagulation in Proliferative Diabetic Retinopathy

NCT04380077Not ApplicableUnknownPrimary

Gas Tamponade for Prevention of Postoperative Vitreous Hemorrhage in Diabetics

Scroll to load more

Research Network

Activity Timeline